BRPI0616054B8 - processo para a preparação de insulina, um análogo de insulina ou um derivado de insulina, tripsina porcina, método para sua produção, dna e vetor - Google Patents

processo para a preparação de insulina, um análogo de insulina ou um derivado de insulina, tripsina porcina, método para sua produção, dna e vetor

Info

Publication number
BRPI0616054B8
BRPI0616054B8 BRPI0616054A BRPI0616054A BRPI0616054B8 BR PI0616054 B8 BRPI0616054 B8 BR PI0616054B8 BR PI0616054 A BRPI0616054 A BR PI0616054A BR PI0616054 A BRPI0616054 A BR PI0616054A BR PI0616054 B8 BRPI0616054 B8 BR PI0616054B8
Authority
BR
Brazil
Prior art keywords
insulin
production
dna
vector
preparation
Prior art date
Application number
BRPI0616054A
Other languages
English (en)
Inventor
Hoh Christoph
Kopetzki Erhard
Geipel Frank
Zocher Frank
Mueller Rainer
Glaser Stephan
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0616054A2 publication Critical patent/BRPI0616054A2/pt
Publication of BRPI0616054B1 publication Critical patent/BRPI0616054B1/pt
Publication of BRPI0616054B8 publication Critical patent/BRPI0616054B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

clivagem de precursores de insulunas por uma variante de tripsina. a presente invenção refere-se à produção de uma variante de tripsina recombinante com especificidade de substrato aumentada para arginina versus usina, em organismos hospedeiros não-animais. além disso, a presente invenção refere-se a uma variante de tripsina recombinante e sua produção. também proporcionados estão o uso de variantes de tripsina pancreática porcina recombinante para clivagem de precursores de insulinas, e kits contendo a variante de tripsina.
BRPI0616054A 2005-09-14 2006-08-26 processo para a preparação de insulina, um análogo de insulina ou um derivado de insulina, tripsina porcina, método para sua produção, dna e vetor BRPI0616054B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05077086.6 2005-09-14
EP05077086 2005-09-14
PCT/EP2006/008380 WO2007031187A1 (en) 2005-09-14 2006-08-26 Cleavage of precursors of insulins by a variant of trypsin

Publications (3)

Publication Number Publication Date
BRPI0616054A2 BRPI0616054A2 (pt) 2011-06-07
BRPI0616054B1 BRPI0616054B1 (pt) 2019-08-06
BRPI0616054B8 true BRPI0616054B8 (pt) 2021-05-25

Family

ID=36190640

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616054A BRPI0616054B8 (pt) 2005-09-14 2006-08-26 processo para a preparação de insulina, um análogo de insulina ou um derivado de insulina, tripsina porcina, método para sua produção, dna e vetor

Country Status (19)

Country Link
US (1) US7981635B2 (pt)
EP (1) EP1926749B1 (pt)
JP (1) JP5027812B2 (pt)
KR (1) KR101304958B1 (pt)
CN (1) CN101253196B (pt)
AR (1) AR055428A1 (pt)
AT (1) ATE517919T1 (pt)
AU (1) AU2006291780B2 (pt)
BR (1) BRPI0616054B8 (pt)
CA (1) CA2621344C (pt)
CY (1) CY1112667T1 (pt)
ES (1) ES2370657T3 (pt)
IL (1) IL189887A (pt)
MX (1) MX2008003362A (pt)
MY (1) MY146082A (pt)
PL (1) PL1926749T3 (pt)
PT (1) PT1926749E (pt)
SI (1) SI1926749T1 (pt)
WO (1) WO2007031187A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
JP5695909B2 (ja) 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
RU2495131C2 (ru) * 2008-02-19 2013-10-10 Байокон Лимитид Способ получения рекомбинантного инсулина гларгина
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
US8975041B2 (en) * 2009-09-10 2015-03-10 Biocon Limited Fusion proteins and method of expression thereof
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013015697A1 (en) * 2011-07-28 2013-01-31 Mabion S.A. A recombinant protein, a polynucleotide encoding it as well as a method of obtaining insulin or its an analogue
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2831262B1 (en) * 2012-03-29 2018-02-14 Biocon Limited Secretion of functional insulin glargine directly into the culture medium through over expression of kex2p intracellularly
CN102816785B (zh) * 2012-05-24 2016-03-09 上海仁会生物制药股份有限公司 一种甘精胰岛素及其类似物的制备方法
CN102994600A (zh) * 2012-12-11 2013-03-27 鲁南新时代生物技术有限公司 甘精胰岛素前体的酶切转化方法
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN108018277A (zh) * 2016-11-04 2018-05-11 江苏万邦生化医药股份有限公司 重组牛胰蛋白酶突变体及其制备方法
KR20190036956A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 지속형 단쇄 인슐린 아날로그 및 이의 결합체
WO2019162423A1 (en) * 2018-02-22 2019-08-29 Sanofi-Aventis Deutschland Gmbh Variants of porcine trypsin
EP3650541A1 (en) * 2018-11-08 2020-05-13 BioPharma Translationsinstitut Dessau Forschungs GmbH Trypsin mutant for c- and n-terminal modification of polypeptides
KR20200080747A (ko) * 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20220112817A (ko) 2019-12-10 2022-08-11 사노피 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법
CN113773391B (zh) * 2020-06-09 2023-10-20 宁波鲲鹏生物科技有限公司 一种门冬胰岛素的制备方法
CN119552847B (zh) * 2025-01-21 2025-04-11 四川大学 链霉菌胰蛋白酶自剪切位点突变体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886043A (en) * 1972-08-24 1975-05-27 Choay Sa Process for preparing pure porcine beta-trypsin
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4885242A (en) 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4808537A (en) 1984-10-30 1989-02-28 Phillips Petroleum Company Methanol inducible genes obtained from pichia and methods of use
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5135868A (en) 1985-10-25 1992-08-04 Phillips Petroleum Company Cultures of yeast of the genus Pichia altered by site selective genomic modification
US5166329A (en) 1985-10-25 1992-11-24 Phillips Petroleum Company DNA encoding the alcohol oxidase 2 gene of yeast of the genus Pichia
US5032516A (en) 1985-10-25 1991-07-16 Phillips Petroleum Company Pichia pastoris alcohol oxidase II regulatory region
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4683293A (en) 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5004688A (en) 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
US5122465A (en) 1989-06-12 1992-06-16 Phillips Petroleum Company Strains of pichia pastoris created by interlocus recombination
EP0548267A4 (en) 1990-09-04 1994-11-23 Salk Inst Biotech Ind Production of insulin-like growth factor-1 in methylotrophic yeast cells
DE19821866A1 (de) 1998-05-15 1999-11-18 Hoechst Marion Roussel De Gmbh Verfahren zur Katalyse von komplexen Reaktionen großer Moleküle mittels an einem polymeren Träger gebundener Enzyme
AU3910000A (en) 1999-03-22 2000-10-09 Zymogenetics Inc. Improved methods for producing proteins in transformed (pichia)
WO2002061064A2 (de) * 2001-02-01 2002-08-08 Roche Diagnostics Gmbh Verfahren zur herstellung von rekombinantem trypsin
JP4629439B2 (ja) 2002-09-24 2011-02-09 ノボザイムス，インコーポレイティド キモトリプシン活性を有する微生物トリプシン変異体及びそれをコードする核酸

Also Published As

Publication number Publication date
US7981635B2 (en) 2011-07-19
PT1926749E (pt) 2011-09-29
CA2621344C (en) 2014-12-16
EP1926749B1 (en) 2011-07-27
PL1926749T3 (pl) 2011-12-30
AU2006291780B2 (en) 2011-12-08
CN101253196B (zh) 2012-09-05
JP5027812B2 (ja) 2012-09-19
KR20080055843A (ko) 2008-06-19
CN101253196A (zh) 2008-08-27
AU2006291780A1 (en) 2007-03-22
US20100196953A1 (en) 2010-08-05
ATE517919T1 (de) 2011-08-15
JP2009507500A (ja) 2009-02-26
SI1926749T1 (sl) 2011-11-30
WO2007031187A1 (en) 2007-03-22
BRPI0616054B1 (pt) 2019-08-06
IL189887A0 (en) 2008-11-03
ES2370657T3 (es) 2011-12-21
CY1112667T1 (el) 2016-02-10
MX2008003362A (es) 2008-03-25
EP1926749A1 (en) 2008-06-04
MY146082A (en) 2012-06-29
AR055428A1 (es) 2007-08-22
CA2621344A1 (en) 2007-03-22
KR101304958B1 (ko) 2013-09-17
BRPI0616054A2 (pt) 2011-06-07
IL189887A (en) 2012-02-29
HK1124341A1 (en) 2009-07-10
WO2007031187A8 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
BRPI0616054B8 (pt) processo para a preparação de insulina, um análogo de insulina ou um derivado de insulina, tripsina porcina, método para sua produção, dna e vetor
MX2009002999A (es) Analogos de insulina resistentes a proteasa.
UY30984A1 (es) Proteinas de fusion de formula m-a para degradar péptidos beta amiloides, composiciones en base a ella, preparacion y aplicaciones.
MX2010001481A (es) Proteasas fungales acidas.
BR112013000114A2 (pt) composição de limpeza e processo para limpeza de um substrato
BRPI0818765A8 (pt) Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo
BRPI0610197B8 (pt) anticorpo de ligação à esclerostina, processo para a produção do mesmo, composição farmacêutica que compreende o dito anticorpo e vetor de clonagem ou expressão
BR112013018385A2 (pt) microorganismo com produtividade de l-aminoácidos aumentada e processo de produção de l-aminoácidos usando o mesmo
AR086199A1 (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BRPI0517238A (pt) formulações que compreendem ecteinascidina e um dissacarìdeo
GT200600264A (es) Modificaciones cristalinas de piraclostrobina
ATE549343T1 (de) Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol
WO2007041610A3 (en) Genes and proteins associated with angiogenesis and uses thereof
AR053259A1 (es) Trigo con nuevo almidon y metodo para producirlo
BRPI0508610A (pt) derivados de aminoácidos
BRPI0607765A2 (pt) pirazolopirimidinas
DK2169050T3 (da) Fremgangsmåde til fremstilling af ikke-allergiske probiotiske bakteriekulturer samt deres anvendelse
DK1912673T3 (da) Fremgangsmåde til at binde effektor-molekyler til proteiner
BRPI0515470A (pt) processos e intermediários para preparação de inibidores de cisteìna protease
BRPI0508969A (pt) compostos orgánicos
BRPI0823018A2 (pt) polinucleotídeo, proteína codificada pelo polinucleotídeo, vetor, transformante, métodos para produzir a proteína e para produzir um conjugado glicuronídeo.
BRPI0618654A8 (pt) variante de zimogênio/protease de fator x/fator xa, ácido nucléico, composição farmacêutica que os contém, vetor, bem como uso dos mesmos
SG170109A1 (en) Proteins, nucleic acids and medicaments
BRPI0512935A (pt) processo para a preparação de aminoácido úteis na preparação de moduladores receptores de peptìdeo
BRPI0518132A (pt) e2-epf5, uma inusitada proteìna e alvo terapêutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/08/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF